Novo Nordisk As Stock Today
| NVO Stock | USD 106.80 0.67 0.63% |
Performance0 of 100
| Odds Of DistressLess than 3
|
Novo Nordisk is selling at 106.80 as of the 30th of November 2024; that is 0.63 percent up since the beginning of the trading day. The stock's open price was 106.13. Novo Nordisk has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Note, on November 14, 2024, Representative Michael McCaul of US Congress acquired $15k to $50k worth of Novo Nordisk AS's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 1982 | Category Healthcare | Classification Health Care |
Novo Nordisk AS, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk is traded on New York Stock Exchange in the United States.. The company has 3.37 B outstanding shares of which 6.05 M shares are now shorted by investors with about 1.26 days to cover. More on Novo Nordisk AS
Moving together with Novo Stock
| 0.78 | HLN | Haleon plc | PairCorr |
| 0.87 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.75 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.81 | ANRO | Alto Neuroscience, | PairCorr |
| 0.73 | SHG | Shinhan Financial | PairCorr |
Moving against Novo Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Novo Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Lars Jorgensen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Novo Resources Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Giant Impact, Baby Boomer Prospects, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNovo Nordisk can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Novo Nordisk's financial leverage. It provides some insight into what part of Novo Nordisk's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Novo Nordisk AS (NVO) is traded on New York Stock Exchange in USA. It is located in Novo Alle 1, Bagsvaerd, Denmark, 2880 and employs 71,880 people. Novo Nordisk is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 472.8 B. Novo Nordisk AS runs under Pharmaceuticals sector within Health Care industry. The entity has 3.37 B outstanding shares of which 6.05 M shares are now shorted by investors with about 1.26 days to cover.
Novo Nordisk AS has about 37.47 B in cash with 108.91 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.57.
Check Novo Nordisk Probability Of Bankruptcy
Ownership AllocationNovo Nordisk AS maintains a total of 3.37 Billion outstanding shares. Roughly 89.83 % of Novo Nordisk outstanding shares are held by general public with 10.17 % by institutional investors. Please note that on November 14, 2024, Representative Michael McCaul of US Congress acquired $15k to $50k worth of Novo Nordisk AS's common stock.
Check Novo Ownership Details
Novo Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 7 M | |
| Polen Capital | 2024-09-30 | 6.9 M | |
| Everett Harris & Co | 2024-09-30 | 6.4 M | |
| State Street Corp | 2024-06-30 | 6.4 M | |
| State Farm Mutual Automobile Ins Co | 2024-09-30 | 6.1 M | |
| Royal Bank Of Canada | 2024-06-30 | 5.9 M | |
| Blackrock Inc | 2024-06-30 | 5.5 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 4.9 M | |
| Capital World Investors | 2024-09-30 | 4.5 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 29.2 M | |
| Jennison Associates Llc | 2024-09-30 | 20.2 M |
Novo Nordisk Historical Income Statement
Novo Stock Against Markets
Novo Nordisk Corporate Directors
| Kasim Kutay | Director | Profile | |
| Sylvie Gregoire | Independent Director | Profile | |
| Mette Jensen | Director, Employee Representative | Profile | |
| Thomas Rantzau | Director, Employee Representative | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.